Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Expansion of Dahej manufacturing facility
Funding capital expenditure for expanding the company's manufacturing capacity at its Dahej facility in Gujarat to meet anticipated demand growth across its product segments.
Upgradation of R&D facility
Capital expenditure toward upgrading and enhancing the company's research and development center located in Vadodara, aimed at broadening the product pipeline.
General corporate purposes
Remaining net proceeds allocated for general corporate purposes including working capital and other business needs.
No documents added yet.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Tatva Chintan Pharma Chem Limited is a specialty chemical manufacturer founded in 1996 and headquartered in Vadodara, Gujarat. The company was incorporated on June 12, 1996, and converted from a private to a public limited company in February 2021, ahead of its July 2021 IPO listing on NSE and BSE. The company operates across four product segments: Structure Directing Agents (SDAs) used in zeolite synthesis for automotive emission control and petrochemical refining, Phase Transfer Catalysts (PTCs) enabling chemical synthesis across multiple industries, Electrolyte Salts and Solutions (ESS) for supercapacitor batteries and energy storage applications, and Pharmaceutical and Agrochemical Intermediates and Specialty Chemicals (PASC). Tatva Chintan holds a notable global position as the world's second-largest manufacturer of SDAs and the only commercial SDA producer in India. Its product portfolio spans over 150 chemical compounds. The company operates manufacturing facilities in Ankleshwar and Dahej in Gujarat, along with a DSIR-approved R&D center in Vadodara. It serves customers across more than 25 countries, including the USA, Germany, Japan, and the UK, with clients in pharmaceuticals, agrochemicals, automotive, and energy storage sectors. Key client relationships include global names such as Merck, Bayer AG, and Divi's Laboratories. The founders - Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, and Snehkar Rasiklal Somani - are first-generation technocrat entrepreneurs who continue to drive the business.
Tatva Chintan raised Rs.150 crore from anchor investors at the upper price band of Rs.1,083 per share, allotting 13,85,040 equity shares on July 15, 2021. Notable anchor participants included Goldman Sachs India, Abu Dhabi Investment Authority (ADIA), Aberdeen Standard Asia Focus Plc, Malabar India Fund, and several domestic mutual fund houses including Axis MF, ICICI Prudential MF, HDFC MF, SBI MF, and Aditya Birla Sun Life MF, along with SBI Life Insurance Company.
Source: RHP • Analysis provided for informational purposes
Last Updated: 25 July 2026, 8:37 PM
Global market leadership in SDAs
The company holds the position of world's second-largest manufacturer of Structure Directing Agents and is the sole commercial producer of SDAs in India, giving it a durable competitive edge in a highly specialized niche.
Diverse and niche product portfolio
Tatva Chintan's four product segments - SDAs, PTCs, electrolyte salts, and pharma/agro intermediates - serve distinct end industries, providing revenue diversification and resilience against sector-specific demand cycles.
Strong export footprint
Exports to over 25 countries, including developed markets like the USA, Germany, and Japan, reduce dependence on domestic demand and provide access to premium global pricing.
Marquee client base
Long-standing relationships with global names such as Merck, Bayer AG, and Divi's Laboratories underscore the quality credentials of the company's products and provide a stable revenue anchor.
Improving financial track record
Revenue grew from Rs.206.80 crore in FY19 to Rs.306.29 crore in FY21, while PAT nearly tripled from Rs.20.54 crore to Rs.52.26 crore over the same period, reflecting strong operating leverage and margin improvement.
Sector concentration in specialty chemicals
A broad slowdown in the specialty chemicals sector, or a structural decline in demand for SDAs due to changes in emission-control technology, could materially affect revenues given product concentration.
Raw material cost volatility
The company's margin profile is sensitive to fluctuations in the prices of key chemical inputs; an inability to pass on cost increases to customers could compress profitability.
Dependence on export markets
A significant share of revenue comes from overseas customers, exposing the company to currency risk, geopolitical disruptions, and regulatory changes in export destinations.
Tatva Chintan Pharma Chem Limited
Plot No. 502/17, GIDC Estate, Ankleshwar - 393 002, District Bharuch, Gujarat, India
View on Maps →MUFG Intime India Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.
Manufacturing concentration in Gujarat
All production facilities are located in Gujarat; a natural disaster, regulatory shutdown, or infrastructure disruption at these sites could materially impact output and deliveries.